Skip to main content
Top
Published in: Lung 4/2013

01-08-2013

The Impact of Neoadjuvant Chemotherapy on the Histopathological Assessment of Thymomas: A Clinicopathological Correlation of 28 Cases Treated with a Similar Regimen

Authors: Annikka Weissferdt, Cesar A. Moran

Published in: Lung | Issue 4/2013

Login to get access

Abstract

Background

Twenty-eight patients treated with neoadjuvant chemotherapy for invasive thymoma are presented.

Methods

The patients were 16 men and 12 women between the ages of 23 and 75 years (mean = 50.8 years). All patients were treated with a similar modality consisting of three courses of cyclophosphamide, doxorubicin, cisplatin, and prednisone prior to their surgical resection.

Results

Grossly, all tumors were ill-defined invasive masses ranging in size from 5 to 18 cm in greatest dimension. Histological evaluation of the resected tumors showed a gamut of histological features, including necrosis, cystic changes, hemorrhage, histiocytic proliferation, calcifications, and cholesterol cleft granulomas in varying proportions. In addition, we found that some histological types of thymoma appeared to be affected less by neoadjuvant chemotherapy, while others, mainly those tumors with a more prominent lymphocytic component, showed more extensive histological changes.

Conclusions

Based on the results of this study, it appears that the response to induction chemotherapy in thymomas may be determined by the histological characteristics of the tumor, with treatment-related changes being present predominantly in cases in which the tumor had a prominent lymphocytic component (WHO type B1 and B2), while tumor viability was highest in cases where the histological type corresponded to spindle cell and atypical thymomas (WHO types A and B3, respectively). In addition, it has to be noted that the histological changes attributed to treatment effect may also be seen in untreated tumors thereby not allowing for definitive separation of treated from nontreated thymomas.
Literature
1.
go back to reference Tormoehlen LM, Pascuzzi RM (2008) Thymoma, myasthenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am 22:509–526PubMedCrossRef Tormoehlen LM, Pascuzzi RM (2008) Thymoma, myasthenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am 22:509–526PubMedCrossRef
2.
go back to reference Moran CA, Weissferdt A, Kalhor N et al (2012) Thymoma I. A clinicopathologic correlation of 250 cases with emphasis on the World Health Organization Schema. Am J Clin Pathol 137:444–450PubMedCrossRef Moran CA, Weissferdt A, Kalhor N et al (2012) Thymoma I. A clinicopathologic correlation of 250 cases with emphasis on the World Health Organization Schema. Am J Clin Pathol 137:444–450PubMedCrossRef
3.
go back to reference Moran CA, Walsh G, Suster S, Kaiser L (2012) Thymoma II. A clinicopathologic correlation of 250 cases with a proposed staging system with emphasis on pathologic assessment. Am J Clin Pathol 137:451–461PubMedCrossRef Moran CA, Walsh G, Suster S, Kaiser L (2012) Thymoma II. A clinicopathologic correlation of 250 cases with a proposed staging system with emphasis on pathologic assessment. Am J Clin Pathol 137:451–461PubMedCrossRef
4.
go back to reference Kim ES, Putnam JB, Komaki R et al (2004) Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation, therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 44:369–379PubMedCrossRef Kim ES, Putnam JB, Komaki R et al (2004) Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation, therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 44:369–379PubMedCrossRef
5.
go back to reference Ridley GJ, Huang J (2010) Induction therapy for locally advanced thymoma. J Thorac Oncol 5:S323–S326CrossRef Ridley GJ, Huang J (2010) Induction therapy for locally advanced thymoma. J Thorac Oncol 5:S323–S326CrossRef
6.
go back to reference Venura F, Rendina EA, Longo F et al (2003) Long-term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg 76:1866–1872CrossRef Venura F, Rendina EA, Longo F et al (2003) Long-term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg 76:1866–1872CrossRef
7.
go back to reference Wright CD, Choi NC, Wain JC et al (2008) Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thorac Surg 85:385–389PubMedCrossRef Wright CD, Choi NC, Wain JC et al (2008) Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thorac Surg 85:385–389PubMedCrossRef
8.
go back to reference Berruti A, Borasio P, Roncari A et al (1993) Neoadjuvant chemotherapy with adriamycin, cisplatin, vincristine, and cyclophosphamide (ADOC) in invasive thymomas: results in six patients. Ann Oncol 4:429–431PubMed Berruti A, Borasio P, Roncari A et al (1993) Neoadjuvant chemotherapy with adriamycin, cisplatin, vincristine, and cyclophosphamide (ADOC) in invasive thymomas: results in six patients. Ann Oncol 4:429–431PubMed
9.
go back to reference Giaccone G, Wilmink H, Paul MA et al (2006) Systemic treatment of malignant thymoma: a decade experience at a single institution. Am J Clin Oncol 29:336–344PubMedCrossRef Giaccone G, Wilmink H, Paul MA et al (2006) Systemic treatment of malignant thymoma: a decade experience at a single institution. Am J Clin Oncol 29:336–344PubMedCrossRef
10.
go back to reference Lemma GL, Lee JW, Aisner SC et al (2011) Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 29:2060–2065PubMedCrossRef Lemma GL, Lee JW, Aisner SC et al (2011) Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 29:2060–2065PubMedCrossRef
11.
go back to reference Macchiarini P, Chella A, Ducci F et al (1991) Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer 68:706–713PubMedCrossRef Macchiarini P, Chella A, Ducci F et al (1991) Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer 68:706–713PubMedCrossRef
12.
go back to reference Kunitoh H, Tamura T, Shibata T et al (2010) A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606). Br J Cancer 103:6–11PubMedCrossRef Kunitoh H, Tamura T, Shibata T et al (2010) A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606). Br J Cancer 103:6–11PubMedCrossRef
13.
go back to reference Jacot W, Quantin X, Valette S et al (2005) Multimodality treatment program in invasive thymic epithelial tumor. Am J Clin Oncol 28:5–7PubMedCrossRef Jacot W, Quantin X, Valette S et al (2005) Multimodality treatment program in invasive thymic epithelial tumor. Am J Clin Oncol 28:5–7PubMedCrossRef
14.
go back to reference Belcher E, Hardwick T, Lal R et al (2011) Induction chemotherapy, cytoreductive surgery and intraoperative hyperthermic pleural irrigation in patients with stage IVA thymoma. Interact Cardiovasc Thorac Surg 12:744–748PubMedCrossRef Belcher E, Hardwick T, Lal R et al (2011) Induction chemotherapy, cytoreductive surgery and intraoperative hyperthermic pleural irrigation in patients with stage IVA thymoma. Interact Cardiovasc Thorac Surg 12:744–748PubMedCrossRef
15.
go back to reference Bretti S, Berruti A, Loddo C et al (2004) Multimodal management of stage III–IVA malignant thymoma. Lung Cancer 44:69–77PubMedCrossRef Bretti S, Berruti A, Loddo C et al (2004) Multimodal management of stage III–IVA malignant thymoma. Lung Cancer 44:69–77PubMedCrossRef
16.
go back to reference Papadopoulos K, Thomas CR (2005) Current chemotherapy options for thymic epithelial neoplasms. Expert Opin Pharmacother 6:1169–1177PubMedCrossRef Papadopoulos K, Thomas CR (2005) Current chemotherapy options for thymic epithelial neoplasms. Expert Opin Pharmacother 6:1169–1177PubMedCrossRef
17.
go back to reference Rea F, Sartori F, Loy M et al (1993) Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg 106:543–549PubMed Rea F, Sartori F, Loy M et al (1993) Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg 106:543–549PubMed
18.
go back to reference Spaggiari L, Casiraghi M, Guarize J (2012) Multidisciplinary treatment of malignant thymoma. Curr Opin Oncol 24:117–122PubMedCrossRef Spaggiari L, Casiraghi M, Guarize J (2012) Multidisciplinary treatment of malignant thymoma. Curr Opin Oncol 24:117–122PubMedCrossRef
19.
go back to reference Venuta F, Rendina EA, Anile M et al (2012) Thymoma and thymic carcinoma. Gen Thorac Cardiovasc Surg 60:1–12PubMedCrossRef Venuta F, Rendina EA, Anile M et al (2012) Thymoma and thymic carcinoma. Gen Thorac Cardiovasc Surg 60:1–12PubMedCrossRef
20.
go back to reference Yokoi K, Matsuguma H, Nakahara R et al (2007) Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol 2:73–78PubMedCrossRef Yokoi K, Matsuguma H, Nakahara R et al (2007) Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol 2:73–78PubMedCrossRef
21.
go back to reference Lucchi M, Ambrogi MC, Duranti L et al (2005) Advanced stage thymomas and thymic carcinomas: results of multimodality treatments. Ann Thorac Surg 79:1840–1844PubMedCrossRef Lucchi M, Ambrogi MC, Duranti L et al (2005) Advanced stage thymomas and thymic carcinomas: results of multimodality treatments. Ann Thorac Surg 79:1840–1844PubMedCrossRef
22.
go back to reference Marulli G, Lucchi M, Margaritora S et al (2011) Surgical treatment of stage III thymic tumors: a multi-institutional review from four Italian centers. Eur J Cardiothorac Surg 39:e1–e7PubMedCrossRef Marulli G, Lucchi M, Margaritora S et al (2011) Surgical treatment of stage III thymic tumors: a multi-institutional review from four Italian centers. Eur J Cardiothorac Surg 39:e1–e7PubMedCrossRef
23.
go back to reference Rajan A, Giaccone G (2011) Chemotherapy for thymic tumors: induction, consolidation, palliation. Thorac Surg Clin 21:107–114PubMedCrossRef Rajan A, Giaccone G (2011) Chemotherapy for thymic tumors: induction, consolidation, palliation. Thorac Surg Clin 21:107–114PubMedCrossRef
24.
go back to reference Rosai J, Levine GD (1976) Tumors of the thymus, Fascicle 13, vol 2. Armed Forces Institute of Pathology, Washington, DC Rosai J, Levine GD (1976) Tumors of the thymus, Fascicle 13, vol 2. Armed Forces Institute of Pathology, Washington, DC
25.
go back to reference Moran CA, Suster S (2001) Thymomas with prominent hemorrhagic and necrotic changes: a clinicopathologic study of 25 cases. Am J Surg Pathol 25:1086–1090PubMedCrossRef Moran CA, Suster S (2001) Thymomas with prominent hemorrhagic and necrotic changes: a clinicopathologic study of 25 cases. Am J Surg Pathol 25:1086–1090PubMedCrossRef
Metadata
Title
The Impact of Neoadjuvant Chemotherapy on the Histopathological Assessment of Thymomas: A Clinicopathological Correlation of 28 Cases Treated with a Similar Regimen
Authors
Annikka Weissferdt
Cesar A. Moran
Publication date
01-08-2013
Publisher
Springer US
Published in
Lung / Issue 4/2013
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-013-9465-5

Other articles of this Issue 4/2013

Lung 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.